title: How to deal with multiple treatment or dose groups in randomized clinical trials? Another approach.
abstract: The multiple test issue is a tricky one. There is no entirely correct solution. It is better to avoid it by careful thinking prior to beginning the experiment. In fundamental and clinical pharmacology, there are several established concepts that allow researchers to minimize the cases where the issue arises.
authors: Jean-Pierre
authors: JP
authors: Boissel
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000069059:Atorvastatin; D002784:Cholesterol / Q000097:blood; D002985:Clinical Protocols; D003627:Data Interpretation, Statistical; D004305:Dose-Response Relationship, Drug; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015233:Models, Statistical; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000706:statistics & numerical data*; D012107:Research Design
chemical_list: D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D002784:Cholesterol; D000069059:Atorvastatin